Rapid health technology assessment of deucravacitinib in the treatment of moderate-to-severe plaque psoriasis
- VernacularTitle:氘可来昔替尼治疗中重度斑块状银屑病的快速卫生技术评估
- Author:
Xing GAO
1
;
Shujing KONG
2
;
Tianya LIU
3
;
Xinran QIU
1
;
Jia HAN
1
Author Information
1. Dept. of Pharmacy，the Affiliated Hospital of Xuzhou Medical University，Jiangsu Xuzhou 221004，China
2. Dept. of Dermatology，the Affiliated Hospital of Xuzhou Medical University，Jiangsu Xuzhou 221004，China
3. Dept. of Anesthesiology，the Affiliated Hospital of Xuzhou Medical University，Jiangsu Xuzhou 221004，China
- Publication Type:Journal Article
- Keywords:
deucravacitinib;
moderate-to-severe plaque
- From:
China Pharmacy
2026;37(1):111-116
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To evaluate the efficacy， safety and cost-effectiveness of deucravacitinib in the treatment of moderate- to-severe plaque psoriasis. METHODS Rapid health technology assessment （HTA） reports， systematic reviews （SR）/meta- analyses， and pharmacoeconomic studies on deucravacitinib for the treatment of moderate-to-severe plaque psoriasis were identified by searching PubMed， Web of Science， Embase， CNKI， Wanfang data and official HTA websites. The search time frame spanned from database inception to July 2025. After literature screening， data extraction， and quality assessment， the study results were subjected to descriptive analysis and synthesis. RESULTS A total of 14 articles were finally included， consisting of 1 HTA report， 10 SR/meta-analyses， and 3 pharmacoeconomic studies. Regarding efficacy， deucravacitinib demonstrated superior efficacy to both placebo and apremilast， with significantly higher response rates for Psoriasis Area and Severity Index 50/75/90/100， Static Physician’ s Global Assessment 0/1， and Dermatology Life Quality Index 0/1， as well as greater reduction in Psoriasis Symptoms and Signs Diary Score （P＜0.05）. Regarding safety， deucravacitinib was well-tolerated. Although the overall incidence of adverse events （AEs） was higher than placebo， it was not significantly different from apremilast. Moreover， the incidence of serious AEs and the rate of discontinuation due to AEs did not differ significantly from placebo （P＞0.05）. Regarding cost-effectiveness， deucravacitinib proved to be more cost-effective than apremilast across multiple healthcare system perspectives， including those of the United States， Japan， and China. CONCLUSIONS Deucravacitinib exhibits favorable efficacy， safety， and cost-effectiveness in the treatment of moderate-to-severe plaque psoriasis. Additional real-world studies are warranted to further refine its evaluation.
